The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, Moshe BaruOmri Laboratories Ltd., Nes Ziona, IsraelAbstract: Hemophilia A is a rare X-linked bleeding disorder caused by lack or dysfunction of coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent injection...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4715a0a1ae424948968807094c17044f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4715a0a1ae424948968807094c17044f
record_format	dspace
spelling	oai:doaj.org-article:4715a0a1ae424948968807094c17044f2021-12-02T02:42:27ZThe use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia1176-91141178-2013https://doaj.org/article/4715a0a1ae424948968807094c17044f2010-08-01T00:00:00Zhttp://www.dovepress.com/the-use-of-pegylated-liposomes-in-the-development-of-drug-delivery-app-a4992https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, Moshe BaruOmri Laboratories Ltd., Nes Ziona, IsraelAbstract: Hemophilia A is a rare X-linked bleeding disorder caused by lack or dysfunction of coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent injections of the missing FVIII often lead to the formation of inhibitory antibodies. Patients who develop high levels of inhibitors must be treated with bypassing agents such as activated FVII (FVIIa). Both FVIII and FVIIa have short half-lives and require multiple injections. Long-acting forms of these proteins would therefore reduce the frequency of injections, improve patient compliance and reduce complications. In this article we present a new platform technology that produces long-acting forms of FVIII and FVIIa and improves the efficacy of hemophilia treatment. This technology is based on the binding of proteins/peptides to the outer surface of PEGylated liposomes (PEGLip). Binding is dependent on an amino acid consensus sequence within the proteins and is highly specific. At the same time, binding is non-covalent and does not require any modification of the therapeutic agent or its production process. Association of proteins with PEGLip results in substantial enhancements in their pharmacodynamic properties following administration. These improvements seem to arise from the association of formulated proteins with platelets prior to induction of coagulation.Keywords: PEGylated liposomes, therapeutic proteins, pharmacodynamics, factor VIII, factor VIIa Rivka YatuvMicah RobinsonInbal Dayan-Tarshishet alDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2010, Iss default, Pp 581-591 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Rivka Yatuv Micah Robinson Inbal Dayan-Tarshish et al The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
description	Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, Moshe BaruOmri Laboratories Ltd., Nes Ziona, IsraelAbstract: Hemophilia A is a rare X-linked bleeding disorder caused by lack or dysfunction of coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent injections of the missing FVIII often lead to the formation of inhibitory antibodies. Patients who develop high levels of inhibitors must be treated with bypassing agents such as activated FVII (FVIIa). Both FVIII and FVIIa have short half-lives and require multiple injections. Long-acting forms of these proteins would therefore reduce the frequency of injections, improve patient compliance and reduce complications. In this article we present a new platform technology that produces long-acting forms of FVIII and FVIIa and improves the efficacy of hemophilia treatment. This technology is based on the binding of proteins/peptides to the outer surface of PEGylated liposomes (PEGLip). Binding is dependent on an amino acid consensus sequence within the proteins and is highly specific. At the same time, binding is non-covalent and does not require any modification of the therapeutic agent or its production process. Association of proteins with PEGLip results in substantial enhancements in their pharmacodynamic properties following administration. These improvements seem to arise from the association of formulated proteins with platelets prior to induction of coagulation.Keywords: PEGylated liposomes, therapeutic proteins, pharmacodynamics, factor VIII, factor VIIa
format	article
author	Rivka Yatuv Micah Robinson Inbal Dayan-Tarshish et al
author_facet	Rivka Yatuv Micah Robinson Inbal Dayan-Tarshish et al
author_sort	Rivka Yatuv
title	The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
title_short	The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
title_full	The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
title_fullStr	The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
title_full_unstemmed	The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
title_sort	use of pegylated liposomes in the development of drug delivery applications for the treatment of hemophilia
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/4715a0a1ae424948968807094c17044f
work_keys_str_mv	AT rivkayatuv theuseofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia AT micahrobinson theuseofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia AT inbaldayantarshish theuseofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia AT etal theuseofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia AT rivkayatuv useofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia AT micahrobinson useofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia AT inbaldayantarshish useofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia AT etal useofpegylatedliposomesinthedevelopmentofdrugdeliveryapplicationsforthetreatmentofhemophilia
_version_	1718402214410584064

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Ejemplares similares